Eupraxia Pharmaceuticals (EPRX) Institutional Ownership $3.69 +0.14 (+4.06%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Eupraxia Pharmaceuticals (NASDAQ:EPRX)Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$162.64KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$14.46K Get EPRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Eupraxia Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data EPRX Institutional Buying and Selling by Quarter Eupraxia Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Millennium Management LLC10,000$31K0.0%N/A0.028% 2/13/2025 Scotia Capital Inc.1,391,719$4.26M0.0%-0.3%3.907% 2/13/2025 Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 2/13/2025 Bank of Montreal Can56,750$178K0.0%+15.2%0.159% 2/6/2025 Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 7/17/2024 180 Wealth Advisors LLC13,000$34K0.0%N/A0.048% (Data available from 1/1/2016 forward) EPRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of EPRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Eupraxia Pharmaceuticals shares: Scotia Capital Inc. ($4.26M), Bank of Montreal Can ($178K), Raymond James Financial Inc. ($37K), and 180 Wealth Advisors LLC ($34K), Millennium Management LLC ($31K).Learn more on EPRX's institutional investors. Which institutional investors have been buying Eupraxia Pharmaceuticals stock? The following institutional investors have purchased Eupraxia Pharmaceuticals stock in the last 24 months: Raymond James Financial Inc. ($23.23K), 180 Wealth Advisors LLC ($13K), Millennium Management LLC ($10K), and Bank of Montreal Can ($7.50K). How much institutional buying is happening at Eupraxia Pharmaceuticals? Institutional investors have bought a total of 53,726 shares in the last 24 months. This purchase volume represents approximately $162.64K in transactions. Which Eupraxia Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Eupraxia Pharmaceuticals stock in the last 24 months: Scotia Capital Inc. ($4.56K). How much institutional selling is happening at Eupraxia Pharmaceuticals? Institutional investors have sold a total of 4,562 shares in the last 24 months. This volume of shares sold represents approximately $14.46K in transactions. Related Companies Organogenesis Institutional Ownership Compass Therapeutics Institutional Ownership Akebia Therapeutics Institutional Ownership PureTech Health Institutional Ownership Altimmune Institutional Ownership ChromaDex Institutional Ownership Kamada Institutional Ownership Mereo BioPharma Group Institutional Ownership Erasca Institutional Ownership Alpha Teknova Institutional Ownership This page (NASDAQ:EPRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts